Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, including its lead candidate INV-101, in development for the treatment of the rare genetic disorder Prader-Willi syndrome (PWS), NASH and other conditions.
Pfizer’s Centers for Therapeutic Innovation and other partnership initiatives champion emerging science and help stakeholders realize the potential of their innovations.
Anthos is developing a pioneering phase 2 monoclonal antibody, abelacimab, as an effective anticoagulant that aims to provide treatment by inhibiting Factor XI to avoid severe bleeding.
The CanVirex platform deploys the oncolytic properties of recombinant measles vectors for innovative cancer treatments. In addition it has now provided a novel COVID-19 vaccine candidate that is approaching clinical trials.
RevoluGen has designed Fire Monkey, a fast, easy-to-use spin column that extracts optimal DNA for long-read sequencing and is already being used in a number of applications.
Genome & Company is developing a microbiome-based add-on therapy for programmed cell death 1/programmed cell death 1 ligand 1 inhibitors. It is also developing novel targeted immune checkpoint inhibitors and believes these two approaches could be combined for personalized therapy.
Actimed Therapeutics is developing anabolic/catabolic transforming agents: a new class of agents to treat cachexia, an often fatal condition associated with many chronic diseases including cancer.
Axial Therapeutics focuses on the gut–brain axis to develop therapeutics to mitigate central nervous system disorders and conditions. The company has built a pipeline of novel small molecules with lead programs in autism spectrum disorder and Parkinson’s disease.
Maximizing the potential of the resident gut microbiome, Kaleido Biosciences is developing novel glycans with the ability to change the metabolic output of the microbiome and have a clinically significant impact across a broad range of diseases.
Precision NanoSystems empowers researchers to develop genetic medicines through its NanoAssmblr technology, helping companies solve drug delivery challenges in both cancer and infectious diseases.
Avalon GloboCare, a leading biotechnology company focusing on cell-based technology and therapeutics, is about to launch clinical trials of its novel blood filtration system to mitigate symptoms of a cytokine storm in COVID-19 patients and a mucosal intranasal spray vaccination against SARS-CoV-2.
With the world’s leading culture collection and reference genome database, and advanced bioinformatics and machine learning systems, UK-based Microbiotica can identify and isolate the full complement of gut bacteria linked to patient phenotype, attracting global interest and partnering deals from big pharma.
Symberix is integrating gut microbiome-targeted ‘symbiotic drugs’ and precision medicine strategies into small-molecule drug discovery, and is seeking corporate partners who are ready to transform pharmaceutical R&D and life cycle management.
Atlantic Healthcare plc is raising funds to advance clinical trials for new chemical entities: alicaforsen for inflammatory bowel disease, and renzapride for gut motility disorders in rare diseases.
Working in partnership with biopharmaceutical companies, InSphero is developing 3D human-cell-based platforms that better predict patient response to new drugs.